FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094610059> ?p ?o ?g. }

• W3094610059 endingPage "277" @default.
• W3094610059 startingPage "268" @default.
• W3094610059 abstract "Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible lung disease. Licensed treatment options for IPF are pirfenidone and nintedanib. The aim of this study was to assess the impact of antifibrotic therapy in patients with IPF with preserved lung function based upon a forced vital capacity (FVC) above 80%. This is a retrospective single-centre cohort study, performed as part of a service evaluation, between January 2007 and September 2018. Patient demographic, treatment and lung function profiles were collected using electronic patient records. A linear mixed model and Kaplan–Meier estimator were utilised to assess changes in FVC and survival over 36 months. A total of 161 patients were included in this study. Mean age was 72 ± 4. Twenty-four (14.9%) received pirfenidone, 86 (53.4%) received nintedanib and 18 (11.2%) received both antifibrotics provided by a compassionate use program (CUP), as the National Institute of Heath and Clinical excellence (NICE) criteria for antifibrotics in the UK is restricted to an FVC 50–80%. Thirty-three (20.5%) patients did not receive treatment. Patients without antifibrotic therapy had a statistically higher baseline FVC compared to other groups: 3.55 l (100%) vs 2.85 l (89.7%) pirfenidone (p = 0.012), vs 2.99 l (93.5%) nintedanib (p = 0.04) and 3.10 l (92.7%) (p = 0.07) for both antifibrotics. FVC decline over 1 year was similar in groups receiving pirfenidone, nintedanib or no treatment [3.72% (158.1 ml) untreated vs 2.77% (139 ml) pirfenidone vs 2.96% (131 ml) nintedanib]; however, it was significantly greater in patients who received both antifibrotics [6.36% (233 ml), p = 0.01]. Use of antifibrotics was associated with a higher median survival post diagnosis; 3.5, 3 and 3.75 years respectively in pirfenidone, nintedanib and both antifibrotic cohorts, compared to the untreated cohort (2.5 years). One in five untreated patients with an average FVC of 100% die within a median of 2.5 years. Antifibrotic therapy was associated with a higher median survival of 3–3.75 years despite treatment groups having lower baseline lung function." @default.
• W3094610059 created "2020-10-29" @default.
• W3094610059 creator A5026986582 @default.
• W3094610059 creator A5045254554 @default.
• W3094610059 creator A5072286347 @default.
• W3094610059 date "2020-10-24" @default.
• W3094610059 modified "2023-10-06" @default.
• W3094610059 title "Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment" @default.
• W3094610059 cites W2001634286 @default.
• W3094610059 cites W2002064506 @default.
• W3094610059 cites W2057292199 @default.
• W3094610059 cites W2104766198 @default.
• W3094610059 cites W2138871107 @default.
• W3094610059 cites W2149661971 @default.
• W3094610059 cites W2167383172 @default.
• W3094610059 cites W2168666423 @default.
• W3094610059 cites W2485988367 @default.
• W3094610059 cites W2524005801 @default.
• W3094610059 cites W2787279971 @default.
• W3094610059 cites W2896596622 @default.
• W3094610059 cites W2922439835 @default.
• W3094610059 doi "https://doi.org/10.1007/s12325-020-01523-7" @default.
• W3094610059 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7854391" @default.
• W3094610059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33098554" @default.
• W3094610059 hasPublicationYear "2020" @default.
• W3094610059 type Work @default.
• W3094610059 sameAs 3094610059 @default.
• W3094610059 citedByCount "12" @default.
• W3094610059 countsByYear W30946100592022 @default.
• W3094610059 countsByYear W30946100592023 @default.
• W3094610059 crossrefType "journal-article" @default.
• W3094610059 hasAuthorship W3094610059A5026986582 @default.
• W3094610059 hasAuthorship W3094610059A5045254554 @default.
• W3094610059 hasAuthorship W3094610059A5072286347 @default.
• W3094610059 hasBestOaLocation W30946100591 @default.
• W3094610059 hasConcept C126322002 @default.
• W3094610059 hasConcept C141071460 @default.
• W3094610059 hasConcept C165637977 @default.
• W3094610059 hasConcept C167135981 @default.
• W3094610059 hasConcept C2777714996 @default.
• W3094610059 hasConcept C2778341716 @default.
• W3094610059 hasConcept C2779832356 @default.
• W3094610059 hasConcept C2780171596 @default.
• W3094610059 hasConcept C3018587741 @default.
• W3094610059 hasConcept C55520419 @default.
• W3094610059 hasConcept C71924100 @default.
• W3094610059 hasConcept C72563966 @default.
• W3094610059 hasConcept C75603125 @default.
• W3094610059 hasConceptScore W3094610059C126322002 @default.
• W3094610059 hasConceptScore W3094610059C141071460 @default.
• W3094610059 hasConceptScore W3094610059C165637977 @default.
• W3094610059 hasConceptScore W3094610059C167135981 @default.
• W3094610059 hasConceptScore W3094610059C2777714996 @default.
• W3094610059 hasConceptScore W3094610059C2778341716 @default.
• W3094610059 hasConceptScore W3094610059C2779832356 @default.
• W3094610059 hasConceptScore W3094610059C2780171596 @default.
• W3094610059 hasConceptScore W3094610059C3018587741 @default.
• W3094610059 hasConceptScore W3094610059C55520419 @default.
• W3094610059 hasConceptScore W3094610059C71924100 @default.
• W3094610059 hasConceptScore W3094610059C72563966 @default.
• W3094610059 hasConceptScore W3094610059C75603125 @default.
• W3094610059 hasIssue "1" @default.
• W3094610059 hasLocation W30946100591 @default.
• W3094610059 hasLocation W30946100592 @default.
• W3094610059 hasLocation W30946100593 @default.
• W3094610059 hasLocation W30946100594 @default.
• W3094610059 hasLocation W30946100595 @default.
• W3094610059 hasOpenAccess W3094610059 @default.
• W3094610059 hasPrimaryLocation W30946100591 @default.
• W3094610059 hasRelatedWork W2555155415 @default.
• W3094610059 hasRelatedWork W2556745572 @default.
• W3094610059 hasRelatedWork W2906041115 @default.
• W3094610059 hasRelatedWork W2986781304 @default.
• W3094610059 hasRelatedWork W2991333012 @default.
• W3094610059 hasRelatedWork W3087338830 @default.
• W3094610059 hasRelatedWork W3087598739 @default.
• W3094610059 hasRelatedWork W3093425191 @default.
• W3094610059 hasRelatedWork W3181815113 @default.
• W3094610059 hasRelatedWork W3212518578 @default.
• W3094610059 hasVolume "38" @default.
• W3094610059 isParatext "false" @default.
• W3094610059 isRetracted "false" @default.
• W3094610059 magId "3094610059" @default.
• W3094610059 workType "article" @default.